| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
449,967 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$81,866,696 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
69 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Felix |
Director |
– • • |
2010-06-08 |
4 |
B |
$11.92 |
$5,814,557 |
I/I |
486,569 |
11,718,889 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2010-06-08 |
4 |
B |
$11.92 |
$160,502 |
I/I |
13,431 |
255,252 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2010-06-07 |
4 |
B |
$11.87 |
$1,336,938 |
I/I |
112,500 |
11,232,320 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2010-06-07 |
4 |
B |
$11.87 |
$36,899 |
I/I |
3,105 |
241,821 |
2.25 |
- |
|
| Lippman Marc E |
Director |
– • – |
2010-06-04 |
4 |
B |
$12.49 |
$249,840 |
D/D |
20,000 |
103,575 |
2.39 |
- |
|
| Baker Felix |
Director |
– • • |
2010-05-25 |
4 |
B |
$11.95 |
$1,793 |
I/I |
150 |
238,716 |
2.17 |
- |
|
| Baker Felix |
Director |
– • • |
2010-05-25 |
4 |
B |
$11.95 |
$64,722 |
I/I |
5,416 |
11,119,820 |
2.25 |
- |
|
| Berger Franklin M |
Director |
– • – |
2010-05-14 |
4 |
OE |
$7.03 |
$119,510 |
D/D |
17,000 |
138,720 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2010-05-13 |
4 |
B |
$13.37 |
$66,865 |
D/D |
5,000 |
121,720 |
2.39 |
- |
|
| Lippman Marc E |
Director |
– • – |
2010-05-10 |
4 |
B |
$11.92 |
$131,995 |
D/D |
11,075 |
83,575 |
2.39 |
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2010-05-03 |
4 |
AS |
$12.95 |
$323,750 |
D/D |
(25,000) |
4,508 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2010-05-03 |
4 |
OE |
$8.24 |
$191,193 |
D/D |
23,203 |
27,711 |
|
- |
|
| Baker Felix |
Director |
– • • |
2010-04-30 |
4 |
B |
$12.56 |
$106,830 |
I/I |
8,447 |
223,060 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2010-04-30 |
4 |
B |
$12.56 |
$3,870,283 |
I/I |
306,022 |
10,552,695 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2010-04-20 |
4 |
OE |
$3.00 |
$30,000 |
D/D |
10,000 |
903,168 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2010-03-30 |
4 |
B |
$12.05 |
$138,528 |
D/D |
11,500 |
116,720 |
2.39 |
- |
|
| Berger Franklin M |
Director |
– • – |
2010-03-12 |
4 |
B |
$11.76 |
$58,794 |
D/D |
5,000 |
105,220 |
2.39 |
- |
|
| Berger Franklin M |
Director |
– • – |
2010-03-10 |
4 |
B |
$11.99 |
$95,920 |
D/D |
8,000 |
100,220 |
2.39 |
- |
|
| Gryska David W |
Director |
– • – |
2010-02-17 |
4 |
OE |
$4.18 |
$16,720 |
D/D |
4,000 |
21,500 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2009-12-29 |
4 |
OE |
$5.11 |
$51,100 |
D/D |
10,000 |
92,220 |
|
- |
|
| Hoth Daniel Floyd Jr |
Director |
– • – |
2009-12-02 |
4 |
OE |
$5.06 |
$52,649 |
D/D |
10,405 |
10,405 |
|
- |
|
| Dobmeier Eric |
Chief Business Officer |
• – – |
2009-10-29 |
4 |
OE |
$4.45 |
$35,083 |
D/D |
6,985 |
19,609 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2009-10-07 |
4 |
OE |
$4.18 |
$20,900 |
D/D |
5,000 |
82,220 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2009-09-08 |
4 |
OE |
$3.00 |
$30,000 |
D/D |
10,000 |
978,168 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2009-08-18 |
4 |
B |
$11.47 |
$56,260 |
D/D |
4,905 |
10,405 |
2.39 |
- |
|
1805 Records found
|
|
Page 54 of 73 |
|
|
